★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Amgen Inc. (AMGN) Moat Analysis
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Amgen is a single-reportable-segment biopharmaceutical company analyzed here as core innovative medicines, rare disease and biosimilars. Q2 2026 total revenue was $10.054B: the residual core category was $7.592B (75.51%), rare disease $1.607B (15.98%), and biosimilars $855M (8.50%). Product sales grew 9% on volume. The verified mechanisms are product-specific patents or regulatory exclusivity and the capital, know-how and validation required for biologics manufacturing; neither eliminates therapeutic competition, payer leverage or contract-manufacturing alternatives. Rare-disease pricing remained strong,TEPEZZA and KRYSTEXXA benefited from 6% and 23% higher net selling prices,but core exposure to loss of exclusivity and policy is visible: Prolia and XGEVA sales fell 32% and 34% amid biosimilar launches, while Medicare price setting pressured Enbrel.
Primary segment
Core Innovative Medicines
Market structure
Competitive
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-08-23
Segments
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Revenue
75.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Rare Disease Portfolio (Horizon + others)
Rare disease and ultra-rare specialty therapeutics (e.g., thyroid eye disease, chronic refractory gout, NMOSD, ANCA-associated vasculitis)
Revenue
16%
Structure
Competitive
Pricing
strong
Share
—
Peers
Biosimilars
Biosimilar biologic drugs (e.g., adalimumab, bevacizumab and other reference biologics)
Revenue
8.5%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Q2 2026 revenue share is the residual after rare disease and biosimilars: $7.592B / $10.054B total revenue, or 75.5122%. The residual includes $517M of collaboration, royalty and other revenue. Amgen reports one operating segment, so no operating-profit share is assigned to this analytical category. Its therapeutic markets are too heterogeneous for a defensible aggregate market-share or HHI estimate. Source: Amgen Q2 2026 Form 10-Q and earnings exhibit filed August 5 and August 4, 2026.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Product-specific patents and regulatory exclusivities delay direct copies, but protection varies sharply across this residual portfolio. The score is 3 because several large products are near or past key expiries, alternative mechanisms compete during exclusivity, and Prolia/XGEVA biosimilar erosion demonstrates the cliff when protection weakens.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and unfavorable litigation outcomes
- Accelerated net price declines after biosimilar/generic entry
- Regulatory or legislative changes that compress exclusivity (e.g., price controls)
Leading indicators
- Patent expiry calendar and major litigation milestones
- FDA/EMA approvals for competing biosimilars/generics
- Net selling price trend (gross-to-net) for mature brands
Counterarguments
- Many therapeutic areas are crowded with alternative mechanisms, limiting pricing even during exclusivity
- Some revenues are concentrated in mature brands already facing net price declines
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Commercial biologics require specialized process characterization, validated plants and regulated quality systems. The barrier is meaningful but not unique to Amgen: large biopharma peers and qualified contract manufacturers possess similar capabilities, so the mechanism is rated 3.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions, quality issues, or supply interruptions
- Technology shifts (e.g., novel modalities) that reduce relevance of existing capacity
- Greater outsourcing/CMO availability lowering entry barriers
Leading indicators
- Batch success/yield trends and supply reliability
- Capacity expansion milestones and capex cadence
- Regulatory inspection outcomes across manufacturing network
Counterarguments
- Other large biopharma firms also possess global manufacturing scale
- Some therapies can be outsourced to specialized CMOs, reducing the advantage
Rare Disease Portfolio (Horizon + others)
Rare disease and ultra-rare specialty therapeutics (e.g., thyroid eye disease, chronic refractory gout, NMOSD, ANCA-associated vasculitis)
Q2 2026 rare-disease revenue was $1.607B / $10.054B total revenue, or 15.9837%: TEPEZZA $576M, KRYSTEXXA $400M, UPLIZNA $335M, TAVNEOS $150M, Ultra-Rare products $149M, and a reported negative $3M rare-disease component of Other products. Amgen reports one operating segment, so no operating-profit share is assigned. The grouped indications lack a coherent aggregate market denominator or reasonably complete competitor shares for market-share or HHI estimation.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS have product-specific patent or regulatory barriers extending into the 2030s in key territories. These barriers block direct copies but not new mechanisms, and protection is neither uniform nor perpetual across the rare-disease basket.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and earlier-than-expected loss of exclusivity
- Off-label substitution or new standards of care displacing branded therapy
- Safety or access controversies reducing uptake
Leading indicators
- Patent litigation filings/outcomes for key assets
- Pipeline disclosures from competitors in the same indications
- Net price and patient access trends in specialty channels
Counterarguments
- Rare disease markets can attract targeted competition due to high pricing and concentrated prescriber base
Biosimilars
Biosimilar biologic drugs (e.g., adalimumab, bevacizumab and other reference biologics)
Q2 2026 biosimilars revenue was $855M / $10.054B total revenue, or 8.5041%: AMJEVITA/AMGEVITA $155M, PAVBLU $287M, WEZLANA/WEZENLA $61M, MVASI $153M, and $199M of other biosimilars. Amgen reports one operating segment, so no operating-profit share is assigned. The portfolio spans several reference-product markets and has no defensible aggregate market-share or HHI denominator.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Biosimilars require reproducible biologics processes, analytical characterization, validated plants and regulatory-quality systems. Amgen has a global internal network, but this is a moderate entry barrier rather than pricing power because large rivals and qualified contract manufacturers can replicate the capability.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Aggressive price competition and tender dynamics compressing returns
- Improved CMO capacity lowering entry barriers
- Interchangeability and payer mandates shifting volume to lowest-price suppliers
Leading indicators
- Biosimilar ASP/price trends by molecule
- Contract wins/losses with major payers and group purchasing organizations
- Supply reliability incidents and backorders
Counterarguments
- Biosimilars often become commoditized quickly; scale does not prevent price wars
Evidence
outstanding material patents for the indicated product
The table documents product, territory, subject matter and expiries; core assets range from expired claims to methods and formulations extending into the 2030s.
Highly specialized knowledge and extensive process and product characterization are required
Supports the expertise/capability barrier in scaling biologics manufacturing.
It can take longer than five years to build, validate and license another manufacturing plant.
Supports high time-to-replicate capacity (capex + regulatory validation).
biologic exclusivity in the United States and regulatory exclusivity in Europe
The filing says TEPEZZA exclusivity runs through 2032 in the United States and 2035 in Europe.
Methods of treatment, including combination therapy
The patent table lists this U.S. KRYSTEXXA protection through October 2040.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Patent challenges and unfavorable litigation outcomes
- Accelerated net price declines after biosimilar/generic entry
- Regulatory or legislative changes that compress exclusivity (e.g., price controls)
- Manufacturing disruptions, quality issues, or supply interruptions
- Technology shifts (e.g., novel modalities) that reduce relevance of existing capacity
- Greater outsourcing/CMO availability lowering entry barriers
Leading indicators
- Patent expiry calendar and major litigation milestones
- FDA/EMA approvals for competing biosimilars/generics
- Net selling price trend (gross-to-net) for mature brands
- Batch success/yield trends and supply reliability
- Capacity expansion milestones and capex cadence
- Regulatory inspection outcomes across manufacturing network
Research AMGN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.